AUTHOR=Sharma Gunjan , Boby Elza , Nidhi Thakur , Jain Ayushi , Singh Jay , Singh Archna , Chattopadhyay Parthaprasad , Bakhshi Sameer , Chopra Anita , Palanichamy Jayanth Kumar 

TITLE=Diagnostic Utility of IGF2BP1 and Its Targets as Potential Biomarkers in ETV6-RUNX1 Positive B-Cell Acute Lymphoblastic Leukemia

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.588101

DOI=10.3389/fonc.2021.588101

ISSN=2234-943X

ABSTRACT=<p>Around 85% of childhood Acute Lymphoblastic Leukemia (ALL) are of B-cell origin and characterized by the presence of different translocations including <italic>BCR-ABL1</italic>, <italic>ETV6-RUNX1</italic>, <italic>E2A-PBX1</italic>, and <italic>MLL</italic> fusion proteins. The current clinical investigations used to identify <italic>ETV6-RUNX1</italic> translocation include FISH and fusion transcript specific PCR. In the current study we assessed the utility of <italic>IGF2BP1</italic>, an oncofetal RNA binding protein, that is over expressed specifically in <italic>ETV6-RUNX1</italic> translocation positive B-ALL to be used as a diagnostic marker in the clinic. Further, public transcriptomic and Crosslinked Immunoprecipitation (CLIP) datasets were analyzed to identify the putative targets of IGF2BP1. We also studied the utility of using the mRNA expression of two such targets, <italic>MYC</italic> and <italic>EGFL7</italic> as potential diagnostic markers separately or in conjunction with <italic>IGF2BP1</italic>. We observed that the expression of <italic>IGF2BP1</italic> alone measured by RT-qPCR is highly sensitive and specific to be used as a potential biomarker for the presence of <italic>ETV6-RUNX1</italic> translocation in future.</p>